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High-level production of violacein 
by the newly isolated Duganella 
violaceinigra str. NI28 and its 
impact on Staphylococcus aureus
Seong Yeol Choi1, Sooyeon Kim1, Sungsoo Lyuck1, Seung Bum Kim2 & Robert J. Mitchell1
A violacein-producing bacterial strain was isolated and identified as a relative of Duganella 
violaceinigra YIM 31327 based upon phylogenetic analyses using the 16S rRNA, gyrB and vioA 
gene sequences and a fatty acid methyl ester (FAME) analysis. This new strain was designated D. 
violaceinigra str. NI28. Although these two strains appear related based upon these analyses, the 
new isolate was phenotypically different from the type strain as it grew 25% faster on nutrient media 
and produced 45-fold more violacein. When compared with several other violacein producing strains, 
including Janthinobacterium lividum, D. violaceinigra str. NI28 was the best violacein producer. For 
instance, the crude violacein yield with D. violaceinigra str. NI28 was 6.0 mg/OD at 24 hours, a value 
that was more than two-fold higher than all the other strains. Finally, the antibacterial activity of D. 
violaceinigra str. NI28 crude violacein was assayed using several multidrug resistant Staphylococcus 
aureus. Addition of 30 μM crude violacein led to a 96% loss in the initial S. aureus population while 
the minimum inhibitory concentration was 1.8 μM. Consequently, this novel isolate represents 
a phenotypic variant of D. violaceinigra capable of producing much greater quantities of crude 
violacein, an antibiotic effective against multidrug resistant S. aureus.
Violacein is a bisindole derived from the condensation of two molecules of tryptophan1. This compound 
is vibrant purple in color and is known to possess a broad biological activity, including performing 
as an antitumor2, antifungal3 and antiviral4. Although not tested within humans to date, violacein has 
been found to have no adverse impact on mice when administered at a concentration of 1 mg/kg2. It 
has recently garnered more attention, however, due to its antibacterial activity against Staphylococcus 
aureus5,6. Tests with this pathogen found that violacein is capable of both acting as a bacteriostatic and 
as a bacteriocidal agent against S. aureus depending on the concentration used7. Moreover, a recent 
study demonstrated that violacein works synergistically with other antibiotics, leading to significantly 
lower minimum inhibitory concentrations for S. aureus, Klebsiella pneumonia and Pseudomonas aerug-
inosa6. All three of these strains are included in the ESKAPE pathogen grouping, a list of multidrug 
resistant bacteria that are becoming more prominent within healthcare environments and nosocomial 
infections8,9. As such, research into the isolation and characterization of violacein producing bacteria, 
the cloning and heterogeneous expression of the vioABCDE genes and the fermentative production of 
violacein has recently blossomed with several key studies reported within the last couple of years10–13.
Violacein is produced by numerous bacterial strains spanning various genera, including 
Chromobacter14,15, Pseudoalteromonas16,17, Janthinobacterium18,19 and Duganella20. Moreover, violacein 
producing bacterial strains have been isolated from diverse environmental locales. Janthinobacterium18,21,22, 
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for instance, was isolated from a glacier, Chromobacteria from a river14,23, Duganella from agricultural 
and forest soils24,25 and Collimonas from the sea26. In this study, we report on the isolation and initial 
characterization of a natural soil isolate, Duganella violaceinigra str. NI28, obtained from a temperate 
forest soil sample taken near Ulsan, South Korea. This strain produces violacein at much higher rate and 
levels than the type strain D. violaceinigra YIM 3132724,27.
Results
Isolation and Identification of D. violaceinigra str. NI28. Various natural bacterial isolates from 
a forest soil sample were grown on nutrient agar (NA) and a single colony that had a dark purple hue, 
suggesting that this strain produced the bisindole violacein, was selected for further characterization. 
Production of crude violacein by this strain was demonstrated using HPLC analysis (Fig. 1). When the 
crude violacein extracted from our new isolate was compared with a commercial preparation of crude 
violacein from Janthinobacterium lividum (Sigma-Aldrich, USA), they were basically indistinguishable 
from each other.
Identification of this strain was next performed using the sequences obtained from three gene loci 
(16S rRNA, gyrB and vioA), with each confirming that it was closely related to Duganella violaceinigra 
YIM 31327 (Figs  2 and 3). The level of sequence similarities between NI28 and D. violaceinigra YIM 
31327 were 98.8% for 16S rRNA gene, 95.9% for gyrB, and 88.8% for vioA, thus indicating that NI28 is 
close, but not identical to Duganella violaceinigra YIM 31327. This relationship was further supported by 
a fatty acid methyl ester (FAME) analysis and comparison of this strain and the type strain, Duganella 
violaceinigra YIM 31327, which showed only minor differences between the two strains (Table 1). Based 
upon the phylogenetic and FAME analyses, this strain was designated D. violaceinigra str. NI28 and 
deposited within the Korea Agricultural Culture Collection (www.genebank.go.kr) (KACC 91951P).
D. violaceinigra str. NI28 is Phenotypically Variant from D. violaceinigra YIM 31327. Although 
both D. violaceinigra str. NI28 and D. violaceinigra YIM 31327 were isolated from forest soils and are 
related genetically based upon the above results, differences were readily apparent between them. For 
instance, D. violaceinigra str. NI28 was found to have trypsin activity using the API ZYM Kit (bioMer-
ieux, France) while D. violaceinigra YIM 31327 was negative for this protease. Furthermore, D. viola-
ceinigra str. NI28 grew remarkably well and produced a significant amount of violacein when cultured 
on NA (Fig.  4A). This was in stark contrast with D. violaceinigra YIM 31327, which grew slower and 
was much less proficient at producing violacein. Figure  4A shows that colonies of D. violaceinigra str. 
NI28 were larger and already producing violacein after 24 hours of growth while those of D. violaceinigra 
YIM 31327 were smaller and still pasty in color. Only after 60 hours did the D. violaceinigra YIM 31327 
colonies achieve a similar size and hue as 24 hour-old the D. violaceinigra str. NI28 colonies (Fig. 4A).
Both of these findings were further evidenced in liquid cultures. As with the colonies, D. violaceinigra 
YIM 31327 was slower to grow in NB liquid media (Fig. 4B). The doubling time for D. violaceinigra YIM 
31327 was 71 minutes based upon the logarithmic growth stage between 3 and 7 hours. In contrast, D. 
violaceinigra str. NI28 doubled every 53.7 minutes, a value that is 25% faster than D. violaceinigra YIM 
31327. Not only did the newly isolated D. violaceinigra str. NI28 grow faster but the optical density after 
24 hours was significantly higher (2.4-fold), as shown in Figs 4B and 5A. We also noticed that D. viola-
ceinigra str. NI28 tended to form flocs when grown in liquid cultures while D. violaceinigra YIM 31327 
Figure 1. HPLC analysis of the violacein extracted from cultures of D. violaceinigra str. NI28 and several 
of the strains employed in this study, showing the presence of violacein (Peak #1–7.5 min) and a second 
peak (Peak #2–10.3 min) that is presumed to be deoxyviolacein. The solvent front (Peak S) is seen at 5.4 min. 
A plot generated using a commercially available violacein extracted from Janthinobacterium lividum is also 
provided for comparison and includes both Peak #1 and Peak #2.
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cells generally remained suspended (data not shown). It is not clear what benefit D. violaceinigra str. NI28 
gains from forming these aggregates, but it was reported that flocs may help protect against predation28.
D. violaceinigra str. NI28 is a Prolific Violacein Producer. All three of these growth characteristics 
(rate, yield and floc formation) may contribute to the higher violacein production seen with this new 
strain. As shown in Fig.  5B, D. violaceinigra str. NI28 was a much more proficient violacein producer 
than D. violaceinigra YIM 31327 under these conditions, generating as much as 18.9 mg/L of crude 
violacein after 24 hours. Further incubation for an additional 24 hours did not improve upon this yield 
with 18.6 mg/L from the two day culture. D. violaceinigra YIM 31327, on the other hand, produced only 
0.42 mg/L during the first 24 hours, and this dropped to 0.38 mg/L after 48 hours. Considering both time 
points, the new strain produced approximately 45-fold more violacein than the type strain.
Although D. violaceinigra str. NI28 is clearly better than D. violaceinigra YIM 31327 at producing 
violacein, the literature also lists several other violacein producing strains, including Chromobacter spe-
cies and Janthinobacterium lividum (Table  2). Consequently, we cultivated each of these strains in NB 
media and determined both the optical density (OD) and crude violacein yields after 24 and 48 hours 
(Fig.  5). The 24 and 48 hour D. violaceinigra str. NI28 optical densities were similar with most of the 
other violacein producing strains but both C. piscinae and C. subtsugae grew to higher ODs (Fig. 5A). 
However, of all the strains tested, the new isolate gave the highest crude violacein yields, particularly 
when grown for 24 hours (Fig. 5B). This figure also shows that it was one of only two strains, other than 
D. violaceinigra YIM 31327, which reached a maximum violacein concentration in 24 hours. This rapid 
and high level production by D. violaceinigra str. NI28 in NB clearly sets this strain apart from the other 
strains, particularly its closest relative, D. violaceinigra YIM 31327, which was the poorest violacein 
producer tested in this study.
When the quantity of violacein produced by all six strains was normalized using the OD, i.e., the 
specific productivity, the newly isolated D. violaceinigra str. NI28 gave the best results (Fig.  5C). This 
was particularly true for the 24 hour sample where the specific productivity was 6.0 mg crude violacein/
OD, a value that was more than twice that obtained for the next closest strain, C. piscinae (2.6 mg crude 
violacein/OD). In comparison, the specific productivity from the type strain, D. violaceinigra YIM 31327, 
was the lowest of all the strains tested (0.33 and 0.34 mg/OD at 24 and 48 hours, respectively). As such, 
D. violaceinigra str. NI28’s high level production of violacein implies that this strain contains more viol-
acein per cell than the other strains, a finding which may contribute to making downstream purification 
of violacein easier.
Duganella violaceinigra str. NI28 Violacein is Bacteriocidal Towards Staphylococcus aureus. 
Several recent articles highlighted the activity of violacein against the human pathogen Staphylococcus 
aureus and showed that a crude violacein concentration of 17 μ M was capable of inhibiting growth of 
this strain5,6. Similarly, we tested the activity of D. violaceinigra str. NI28 violacein extracts with two S. 
aureus isolates that were obtained from culture repositories (ATCC 25923 and the CCARM strains) and 
from a patient infected with a multidrug-resistant S. aureus (Clinical) (Table 3). As shown in Fig. 6, the 
Figure 2. Phylogenetic tree using the 16S rRNA gene sequence. The numbers at nodes indicate levels of 
bootstrap support (%) based on 1,000 resampled dataset. The bars corresponds to 0.01 or 0.05 substitutions 
per nucleotide. In parentheses are the nucleotide sequence accession numbers of corresponding strains.
www.nature.com/scientificreports/
4Scientific RepoRts | 5:15598 | DOi: 10.1038/srep15598
crude violacein prepared from D. violaceinigra str. NI28 was capable of blocking growth of both S. aureus 
strains when added to a final concentration of 15 μ M, or approximately 5 mg/L. Moreover, this concentra-
tion led to a 70% loss in viability after 24 hours when compared with the initial S. aureus colony-forming 
unit (CFU) values while higher concentrations led to comparably greater losses in viability. For instance, 
60 μ M violacein reduced both S. aureus populations by an average of 99.5% when compared with the 
initial CFU numbers.
We next tested the efficacy of the D. violaceinigra str. NI28 crude violacein against a selection of 
bacterial strains, including several multidrug resistant S. aureus strains that have diverse antibacterial 
resistance footprints according to the EUCAST breakpoints (Table 3). Table 4 lists the minimal inhibi-
tory concentrations (MICs) of violacein found for each of the strains tested in this study. Growth of all 
S. aureus cultures was inhibited by a violacein concentration of 15 μ M (Table 4) regardless of the anti-
biotic resistant nature of the pathogen. Furthermore, MIC tests performed using Pseudomonas aerugi-
nosa and Klebsiella pneumoniae found both of these pathogens were resistant to violacein. Parallel tests 
performed with a commercially available crude violacein from J. lividum gave identical results (Table 4), 
demonstrating that the bioactivity of the crude violacein from D. violaceinigra str. NI28 against these 
pathogens is equivalent to that of the commercially available J. lividum crude violacein.
Discussion
As a bacterial secondary metabolite, violacein has garnered renewed interest lately. A vibrant violet-hued 
bisindole derivative of tryptophan, violacein has been shown to have multiple biological activities, includ-
ing as an anticancer2,13 and antibiotic, particularly against S. aureus. It is this multifaceted character of 
violacein, and the fact that resistance to this antibiotic has not yet been described, that makes it an 
attractive product for bioprocesses.
Figure 3. Phylogenetic analysis of the new isolate using the (A) gyrB and (B) vioA gene sequences. 
The numbers at nodes indicate levels of bootstrap support (%) based on 1,000 resampled dataset. The bars 
corresponds to 0.01 or 0.05 substitutions per nucleotide. The nucleotide sequence accession numbers of the 
corresponding strains are listed in theparentheses.
www.nature.com/scientificreports/
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Fatty Acid (%) NI28 YIM 31327
Straight Chain
 C10:0 − 0.4
 C12:0 5.05 6.54
 C14:0 2.99 1.04
 C16:0 33.28 31.42
Branched
 Iso-C10:0 0.12 − 
Unsaturated
 C14:1 − 0.26
 C18:1 3.8 3.69
Hydroxy
 C10:0 − 3.82
 C12:0 2.66 1.74
 C14:0 3.41 3.6
Sum in Feature 3 48.68 47.49
Table 1.  Fatty acid methyl ester (FAME) comparison between D. violaceinigra str. NI28 and D. violaceinigra 
YIM 31327. *Summed features represent two or three fatty acids that cannot be separated by the Microbial 
Identification System. The fatty acids included in Feature 3 consist of C16 :1ω 7c and/or iso-C15:0 2-OH.
Figure 4. D. violaceinigra str. NI28 grows faster than D. violaceinigra YIM 31327. (A) Image of each strain 
grown on NB agar plates for 24 and 60 hours. The upper and bottom regions are from the same plate. Note 
the more rapid colony development and violacein production by D. violaceinigra str. NI28. (B) Growth of 
both strains in NB media confirming that D. violaceinigra str. NI28 grows faster. The data for each strain was 
obtained from three independent cultures.
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This study reports on the isolation and characterization of a novel high-level violacein-producing 
bacterial strain. This strain was identified as Duganella using both FAME and phylogenetic analyses and 
found to be similar based upon these tests with the type strain D. violaceinigra YIM 31327, which also 
produces violacein. However, when these two strains were compared with each other, we found that they 
were quite distinct from each other. For instance, the new strain grew faster and produced significantly 
more violacein (45-fold) than D. violaceinigra YIM 31327. Moreover, this new isolate also has a tendency 
to form flocs, another attribute that has been noted as being more economical when harvesting microbial 
biomass29. When this strain, D. violaceinigra str. NI28, was compared with several other well-known 
violacein producers, it grew faster, produced more violacein and had the best yields per biomass. Both 
Figure 5. Growth and violacein production by several different bacterial strains. (A) Optical density 
values for each culture at 0, 24 and 48 hours. (B) Violacein concentration within each culture at 24 and 
48 hours, showing the rapid and high level violacein generation by D. violaceinigra str. NI28 as compared 
with the other strains. (C) The relative concentration of violacein based upon the culture density, illustrating 
that D. violaceinigra str. NI28 gave the greatest yields.
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the rapid, high-level production by D. violaceinigra str. NI28 and its higher concentration within the cells 
are clearly advantageous and desirable from an economic viewpoint since the first would reduce the time 
needed for production of violacein while the second minimizes the biomass needed for its subsequent 
extraction and purification. These characteristics of D. violaceinigra str. NI28 make it a potentially attrac-
tive and alternative strain for the commercial production of violacein.
When the violacein from D. violaceinigra str. NI28 cultures was purified and analyzed, we found that 
it was similar with a commercially available preparation from J. lividum, as well as that extracted from the 
various strains employed in this study. As noted above, this bisindole is quite effective against S. aureus 
and, as such, this pathogen was selected for this study due to its overwhelming presence within noso-
comial infections30,31 and its broad resistance to antibiotics32. Previous studies reported the minimum 
inhibitory concentration (MIC) of violacein was 5.7 μ g/ml, or approximately 17 μ M, with S. aureus6. The 
preparation from D. violaceinigra str. NI28 was equally potent with an MIC of 5 μ g/ml, or approximately 
15 μ M. This concentration was not only inhibitory but also bactericidal as it led to a 69% reduction in 
the viability with the ATCC strain and a 78% decrease with the clinical isolate. Both of these findings 
clearly illustrate that the crude violacein purified from cultures of D. violaceinigra str. NI28 is capable of 
not only inhibiting S. aureus growth but also killing this pathogen.
Moreover, the multidrug resistant nature of the S. aureus strains did not contribute to their survival 
when exposed to violacein. Tests using a total of five S. aureus strains with different antibiotic resistance 
Strains Description Referencea
Duganella violaceinigra str. NI28 Violacein producer This study
Duganella violaceinigra Violacein producer YIM 31327
Janthinobacterium lividum Violacein producer ATCC 12473
Chromobacterium pseudoviolaceum Violacein producer ATCC 7461
Chromobacterium piscinae Violacein producer LMG 3947
Chromobacterium subtsugae Violacein producer DSM 17043
Staphylococcus aureus Type strain ATCC 25923
Staphylococcus aureus Multidrug Resistant (MRSA) Clinical Isolate
Staphylococcus aureus − CCARM 0201
Staphylococcus aureus Multidrug Resistant (MRSA) CCARM 3090
Staphylococcus aureus Multidrug Resistant (MRSA) CCARM 3840
Klebsiella pneumoniae Human pathogen ATCC 13883
Pseudomonas aeruginosa PAO1 Human pathogen
Table 2.  Strains used in this study. aYIM (Yunnan Institute of Microorganisms); ATCC (American Type 
Culture Collection); LMG (Belgian Coordinated Collection of Microorganisms); DSM (Deutsche Sammlung 
von Mikroorganismen und Zellkulturen GmbH); CCARM (Culture Collection of Antimicrobial Resistant 
Microbes).
Strain Vana Rifa Cipa Clina Oxaa Erya Genta Toba
S. aureus
 ATCC 25923 19–21(S)b 32–36(S) 30–31(S) 27–30(S) 22–25(S) 27–30(S) 24–27(S) 26–27(S)
 Clinical Isolate 21–22(S) 0(R) 11–18(R) 0(R) 0(R) 0(R) 0(R) 0(R)
 CCARM 0201 18–19(S) 31–34(S) 25–30(S) 23–28(S) 25–27(S) 21–30(S) 22–24(S) 20–23(S)
 CCARM 3090 19–21(S) 36–38(S) 0(R) 0(R) 0(R) 0(R) 26–27(S) 26–28(S)
 CCARM 3840 19–24(S) 33–40(S) 0(R) 0(R) 0(R) 0(R) 0(R) 0(R)
K. pneumoniae ATCC 13883 NDc ND 35–37(S) ND ND ND 22–25(S) 24–25(S)
P. aeruginosa PAO1 ND ND 33–35(S) ND ND ND 23–24(S) 29–30(S)
Table 3.  Antibiotic susceptibility results. Tests were performed using disc-diffusion plates with  
the results listed representing the range of diameters (mm) measured for the inhibitory zones from three 
independent tests. Strains showing resistance are listed in bold. aThe antibiotics tested were vancomycin 
(Van), rifampin (Rif), ciprofloxacin (Cip), clindamycin (Clin), oxacillin (Oxa), erythromycin (Ery), 
gentamycin (Gent) and tobramycin (Tob). bRange of diameters (mm) seen for the inhibitory zones.  
(S) – susceptible; (R) – resistant. cNot done.
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footprints, showing that several were multidrug resistant (Table 3), found that each was equally sensitive 
to the crude violacein from D. violaceinigra str. NI28, with MICs of 15 μ M (Table 4). These values are 
basically identical with that reported by Subramaniam et al. (2014), where they found the MIC for S. 
aureus to be 5.7 μ g/ml (17 μ M). When we performed further MIC tests in a modified M9 media, the 
effective concentration dropped to only 0.9 or 1.8 μ M, a value that is significantly lower than those found 
with the Mueller-Hinton media and is likely attributable to the nutrient poor nature of the medium used. 
Similar impacts of the media richness and bacterial responses has been documented previously33, where 
the authors found the use of a nutrient poor medium made the bacteria more susceptible to chemicals. 
Consequently, the use of a minimal media within this study increased the susceptibility of the bacteria 
to violacein and does not indicate a greater activity against these pathogens. Further evidence of this is 
seen in the similar MICs obtained with the commercially available J. lividum crude violacein, which was 
also significantly lower (Table 4). The HPLC analyses of these two crude violacein preparations, shown 
in Fig. 1, found them to be similar. The second peak was not identified but is presumed to be deoxyvio-
lacein since this compound is also known to be generated alongside violacein. Although it may also play 
a role and contribute to S. aureus inhibition, a recent study found that deoxyviolacein was less effective 
against this pathogen than violacein34.
Two additional pathogens were also tested, P. aeruginosa PAO1 and K. pneumoniae, but neither of 
these was sensitive to either of the violacein samples (Table 4). This was not unexpected as several articles 
previously highlighted the tendency for Gram-positive strains to be more sensitive than Gram-negative 
strains6,25. These findings suggest that the presence of the outer membrane within these bacteria provides 
protection against violacein and its activity and is an area for further evaluation in a later study.
Figure 6. Inhibition and killing of Staphylococcus aureus by D. violaceinigra str. NI28 violacein. Two  
S. aureus strains were tested: ATCC 25923 and a clinical isolate. The initial CFU was determined just prior 
to addition of the violacein. The viability of the other samples was determined after a 24 hour exposure 
to the violacein at the concentrations listed, showing that the addition of 15 μ M or greater violacein was 
bactericidal towards both pathogenic strains. The samples were prepared so that each had the same amount 
of DMSO (1.3%) added. The concentrations listed are based upon the commercial standard.
Strain
Commercial 
Violacein
NI28 
Violacein
Commercial 
Violacein
NI28 
Violacein
Mueller-Hinton Media Modified M9 Media
S. aureus
 ATCC 25923 15 μ M 15 μ M 1.8 μ M 1.8 μ M
 Clinical Isolate 15 μ M 15 μ M 0.9 μ M 1.8 μ M
 CCARM 0201 15 μ M 15 μ M 1.8 μ M 1.8 μ M
 CCARM 3090 15 μ M 15 μ M 1.8 μ M 1.8 μ M
 CCARM 3840 15 μ M 15 μ M 0.9 μ M 1.8 μ M
K. pneumoniae ATCC 13883 >30 μ M >30 μ M >30 μ M >30 μ M
P. aeruginosa PAO1 >30 μ M >30 μ M >30 μ M >30 μ M
Table 4.  Minimum inhibitory concentration results. The concentration listed is that which showed no 
growth after 24 hours in the resazurin microplate tests using the modified M9 media. The highest crude 
violacein concentration tested was 60 μ M.
www.nature.com/scientificreports/
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In conclusion, a violacein-producing strain was isolated from a forest soil sample in Ulsan, South 
Korea. This strain, D. violaceinigra str. NI28, produces violacein at quicker and at higher levels than 
other comparable strains, particularly the type strain D. violaceinigra YIM 31327, when grown under 
the conditions used in this study. Although the violacein concentrations produced in this study are low, 
a group recently reported achieving as much as 0.82 g/L with C. violaceum by optimizing the conditions 
for fermentation and the media used35. As D. violaceinigra str. NI28 is a new strain and, based upon the 
violacein production and yields found in this study, is generally equivalent to or better than the other 
strains tested, expanding its growth and violacein production through similar techniques would likely 
increase the yields. Moreover, other recent studies have shown the successful expression of the vioAB-
CDE operon within other bacterial hosts to produce even higher levels of violacein. The characteristics 
of D. violaceinigra str. NI28 make its vioABCDE operon an interesting addition to these studies and, as 
such, cloning of these genes for their heterologous expression may likewise be beneficial.
Methods
Isolation of Duganella violaceinigra str. NI28. The novel strain characterized in this study, i.e., 
Duganella violaceinigra str. NI28, was isolated using soil obtained from a temperate forest nearby the 
campus. For this, a 50 g sample of soil was mixed with 500 ml of sterile tap water and shaken at 30 °C for 
2 hours. Afterwards, the soil particulates were centrifuged at 500 × g for 5 minutes and the supernatant 
sampled. Aliquots (100 μ l) of this solution were spread out on nutrient agar (NA) (1.6% agar; Difco, 
USA) plates. A total of forty plates were prepared and these were then incubated at 30 °C for 48 hours. A 
single colony showing a violet hue on one of the plates was selected for further evaluation.
Bacterial Strains and Growth. The bacterial strains used in this study are listed in Table 2. All of 
the strains were grown from − 80 °C freezer stocks that were prepared individually. For the violacein 
producing strains, the stocks were prepared by adding DMSO (Sigma-Aldrich, USA) to a final concen-
tration of 10%. The Staphylococcus aureus strains were stored using glycerol (Sigma-Aldrich, USA) at a 
final concentration of 25%.
Each violacein producing strain was struck out on NA plates and grown at 30 °C overnight. A single 
colony was transferred to a sterile 15 ml conical tube (SPL, Korea) containing 3 ml of nutrient broth 
(Difco, USA). This culture was grown at 30 °C and 250 rpm overnight. To 20 ml of fresh NB medium in 
a 100 ml baffled flask to increase aeration, 2 ml (10% v/v) of the overnight culture was added and this was 
again shaken at 30 °C and 250 rpm for 48 hours. At set times during this cultivation (24 and 48 hours), 
aliquots were taken to determine the culture optical density and violacein concentration as described 
below. For the growth curves shown in Fig. 4, 100 ml cultures were cultivated within 250 ml flasks. All 
the other strains were grown using the same protocols except at 37 °C and in TSB media (Difco, USA). 
Other media was used for the antibiotic resistance characterization and minimum inhibitory concentra-
tion determination as described below.
Identification of D. violaceinigra str. NI28 by 16S using phylogenetic markers. The genus of 
isolate NI28 was identified using three genes, namely 16S rRNA, gyrB and vioA. The primers for PCR 
amplification of the genes were 27f (5′ -AGA GTT TGA TCM TGG CTC AG-3′ ) and 1492r (5′ -GGT 
TAC CTT GTT ACG ACT T-3′ ) for the 16S rRNA gene, Up-1G (5′ -YGC SGG CGG YAA GTT CGA-3′ ) 
and Up-2G (5′ -CCR TCG ACG TCV GCR TCG GT-3′ ) for gyrB36, and VPA3 (5′ -CCR CAG CTS CAY 
CCG CAT TTC CAG-3′ ) and VPA4 (5′ -CAG GCY GCC CTC CAT CCA GCC RCA-3′ ) for vioA26. The 
PCR conditions for the gyrB gene were: 95 °C for 5 minutes followed by 35 cycles of 95 °C for 30 s, 60 °C 
for 15 s and 72 °C for 90 s. The final extension was at 72 °C for 5 minutes. The vioA gene was amplified 
in the same manner but with an annealing temperature of 62 ºC. The phylogenetic analysis between 
NI28 and the related taxa including Duganella was performed using MEGA 6.037. Neighbor-joining trees 
were inferred based on Jukes-Cantor evolutionary distances for each gene. The trees were evaluated 
using bootstrap analysis with 1,000 resampled datasets. The sequences of each gene from strain NI28 
were deposited within the GenBank database under the accession numbers (KM087998, KM087999 and 
KM088000).
Fatty Acid Methyl Ester Preparation and Analysis. Colonies of D. violaceinigra str. NI28 and D. 
violaceinigra YIM 31327 grown on NA plates were used for this analysis. To prepare the samples, several 
colonies were transferred to a test tube and 1 ml of Reagent #1 (45 g NaOH (ACS Grade, Sigma-Aldrich, 
USA), 150 ml HPLC Grade methanol (Sigma-Aldrich, USA) and 150 ml deionzed distilled water) was 
added. After vortexing to suspend the bacteria, this sample was placed at 100 °C for 5 minutes, vor-
texed once more and then incubated at 100 °C once more for 25 minutes. Afterwards, the tubes and 
samples were cooled down in a room temperature water bath. To initiate methylation of the fatty acids, 
2 ml of Reagent #2 (325 ml 6 N HCl (Sigma-Aldrich, USA) mixed with 275 ml HPLC Grade methanol 
(Sigma-Aldrich, USA)) was added to each tube, which was vortexed and then incubated at 80 °C for 
10 minutes. Afterwards, the tubes were quickly cooled by gently shaking them in a room temperature 
water bath. To each tube, 1.25 ml Reagent #3 (prepared using an equal volume of HPLC Grade hexane 
(Sigma-Aldrich, USA) and HPLC Grade methyl tert-butyl ether (Sigma-Aldrich, USA)) was added and 
the contents were gently mixed end-over-end for 10 minutes using a rotator. The aqueous phase was 
www.nature.com/scientificreports/
1 0Scientific RepoRts | 5:15598 | DOi: 10.1038/srep15598
removed from the tubes and discarded. To remove any free fatty acids, the samples were washed with 
3 ml of Reagent #4 (10.8 g ACS Grade sodium hydroxide in 900 ml deionized distilled water) by gently 
mixing them as above for 5 minutes. Once more, the aqueous phase was removed and discarded. The 
organic phase was used for gas chromatography (GC) analysis. For the GC analysis, the column was 
an Ultra 2 (25 m, 0.2 mm, Agilent, USA). The protocol used was the same as used previously for the D. 
violaceinigra type strain24.
Phenotypic Assessment of D. violaceinigra str. NI28. A comparative phenotypic analysis of 
D. violaceinigra str. NI28 and YIM 31327 was performed using the API 20NE and API ZYM test kits 
(bioMerieux, France) according to the manufacturer’s suggested protocol.
Extraction and HPLC Analysis of the Violacein Produced by D. violaceinigra str. NI28. After 
growth for 24 and 48 hours, 1 ml of the culture was pelleted by centrifugation for one minute at 16,200 × g 
and room temperature. After aspirating off the media, the pellet was resuspended in an equal volume 
of ethanol and shaken at 37 °C and 250 rpm for 24 hours. The solution was then transferred to another 
centrifuge tube and the absorbance measured at 575 nm. This value was used to calculate the violacein 
concentration using an extinction coefficient of 73.4 L mg−1 cm−1 12. The crude violacein concentration 
within the ethanol extracts was determined using standards prepared with a crude violacein purchased 
from Sigma-Aldrich (USA, Cat. No. V9389).
The crude violacein sample was also analyzed using HPLC 1200 (Agilent, USA) as described previ-
ously12. For this, 10 μ l samples of the ethanol extracted violacein were analyzed using a C-18 column 
(Hypersil ODS, 5 μ m, 250 × 4.6 mm) at 30 ºC. The mobile phase was 50% denatured ethanol (HPLC 
Grade, Sigma-Aldrich, USA) and detection was performed at 575 nm using an Agilent 1260 Infinity 
ELSD. The violacein concentration within the ethanol extracts was determined as described above using 
crude violacein purchased from Sigma-Aldrich (USA, Cat. No. V9389) as a known standard. For the 
viability and MIC tests, the ethanol was dried off and the crude violacein powder solubilized within 
DMSO at a known concentration.
Antibiotic Disc Diffusion Assay. Each of the strains characterized is listed in Table  3. Each strain 
was grown on tryptone soy agar plates overnight and several colonies were transferred to 5 ml fresh 
sterile tryptone soy broth (TSB). They were then grown for overnight (250 rpm, 37 ºC), diluted into fresh 
sterile TSB (0.1%) and grown until the optical density (OD) was equivalent to a 0.5 McFarland standard, 
which was provided with the API tests used above. After reaching this OD, the culture was spread out on 
Mueller-Hinton agar plates using sterile, non-toxic cotton swabs. The plates were air-dried for 10 minutes 
before applying the antibiotic discs (BBL Sensi-Disc, BD, U.S.A.). The antibiotics tested were ciprofloxa-
cin, clindamycin, erythromycin, gentamycin, oxacillin, rifampin, tobramycin and vancomycin. The zones 
of growth inhibition were determined after 18 hours of incubation at 37 °C for all the antibiotics except 
vancomycin and oxacillin, which were determined after 24 hours. Strain resistance was determined using 
the latest breakpoint tables available at the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) website (http://www.eucast.org/clinical_breakpoints/).
Violacein Killing of Staphylococcus aureus. The extracted crude violacein was concentrated by 
drying down multiple preparations under nitrogen gas and resuspending it in DMSO. The concentration 
was once more determined as described above.
Two different strains of S. aureus (ATCC 25923 and a clinical isolate) were used to evaluate the activ-
ity of the violacein extracted from P. sp. NI28 cultures. After growth overnight, the S. aureus cultures 
were diluted 1:100 into 3 ml M9 modified minimal media containing 1 g/L tryptone and 0.2% glucose. 
We chose this media as it is slightly modified from one that was published recently and used for MIC 
testing38. Violacein (M.W. 343.33) in DMSO was added to these cultures at a final concentration of 0, 15, 
30 or 60 μ M. The final DMSO concentration in all cultures was 1.3%. The cultures were then incubated 
at 37 °C and 250 rpm for 24 hours, after which the viable S. aureus numbers were determined using serial 
dilutions of the cultures that were spread out on TSB agar plates and grown overnight at 37 ºC.
Minimum Inhibitory Concentration Determination. The crude violacein samples were prepared 
as above and the commercial violacein was purchased from Sigma-Aldrich (USA). Determining the 
minimum inhibitory concentration was performed as described previously using resazurin39, with 
some modification. Briefly, the bacteria were grown overnight in cation adjusted Mueller-Hinton broth 
(10 mg/L of both Ca2+ Mg2+) medium at 37 °C and 250 rpm and then sub-cultured into fresh media and 
grown to an OD600nm of 0.1 under the same conditions. When they reached this OD, the cultures were 
diluted 1:100 into either cation adjusted Mueller-Hinton broth or modified M9 minimal media (contain-
ing 1 g/L tryptone and 0.2% glucose).
The media for the plate was prepared separately. Briefly, 3 ml of a sterile 0.2% resazurin solution pre-
pared using distilled water was diluted into 12 ml of the modified M9 media. A 1.5 ml sample of this was 
then taken and crude violacein was added to a final concentration of 60 μ M. Within the first row of the 
plate (row A), 200 μ l of either cation adjusted Mueller-Hinton broth or modified M9 media containing 
60 μ M violacein was added. Each of the other wells had 100 μ l of the same media containing resazurin 
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added to them. The violacein containing media was then diluted two-fold sequentially from rows A-G 
but not into the final row (H). To the wells, 100 μ l of the prepared bacterial cultures were added, giving a 
final cell concentration of 4 × 105 CFU/well, the highest violacein concentration of 30 μ M and a resazurin 
concentration of 0.02% in each well. The final row (H) was used as a positive control to demonstrate that 
each bacterium was capable of growing. Each strain was tested independently in triplicate. The control 
wells had only the media and the violacein added to them to test for contamination. All the wells had a 
final DMSO concentration of 1%.
Data Analysis. Each of the experiments was performed in triplicate for error analysis. The standard 
deviations are presented as error bars in each graph where appropriate.
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